Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells

Journal of Virology

Volumn 76, Issue 22, 2002, Pages 11530-11540

  Pajusola, Katri ^a   Gruchala, Marcin ^a   Joch, Hana ^a   Lüscher, Thomas F ^a   Ylä Herttuala, Seppo ^a   Büeler, Hansruedi ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; PROTEASOME INHIBITOR; PROTEOHEPARAN SULFATE; VIRUS RECEPTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TYPE; CONTROLLED STUDY; ENDOSOME; ENDOTHELIUM CELL; EXPRESSION VECTOR; EXTRACELLULAR MATRIX; GENETIC TRANSDUCTION; GOLGI COMPLEX; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS EXPRESSION; VIRUS GENE; VIRUS INFECTION;

ANIMALS; CAROTID ARTERIES; CELL LINE; CELLS, CULTURED; DEPENDOVIRUS; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MALE; RABBITS; TRANSDUCTION, GENETIC;

EID: 0036828063     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.22.11530-11540.2002     Document Type: Article

References (41)

1. Bantel-Schaal, U., B. Hub, and J. Kartenbeck. 2002. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J. Virol. 76:2340-2349.
2. Bartlett, J. S., R. Wilcher, and R. J. Samulski. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74:2777-2785.
3. Berns, K. I., and C. Giraud. 1996. Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 218:1-23.
4. Byun, J., J. M. Heard, J. E. Huh, S. J. Park, E. A. Jung, J. O. Jeong, H. C. Gwon, and D. K. Kim. 2001. Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J. Mol. Cell Cardiol. 33:295-305.
5. Chao, H., Y. Liu, J. Rabinowitz, C. Li, R. J. Samulski, and C. E. Walsh. 2000. Several log increase in therapeutic transgene delivery by distinct adenoassociated viral serotype vectors. Mol. Ther. 2:619-623.
6. Cross, M. J., and L. Claesson-Welsh. 2001. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22:201-207.
7. Douar, A. M., K. Poulard, D. Stockholm, and O. Danos. 2001. Intracellular trafficking of adeno-associated virus vectors: Routing to the late endosomal compartment and proteasome degradation. J. Virol. 75:1824-1833.
8. Duan, D., Q. Li, A. W. Kao, Y. Yue, J. E. Pessin, and J. F. Engelhardt. 1999. Dynamin is required for recombinant adeno-associated virus type 2 infection. J. Virol. 73:10371-10376.
9. Duan, D., Y. Yue, Z. Yan, J. Yang, and J. F. Engelhardt. 2000. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Investig. 105:1573-1587.
10. Edgell, C. J., C. C. McDonald, and J. B. Graham. 1983. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. USA 80:3734-3737.
11. Eslami, M. H., S. P. Gangadharan, X. Sui, K. K. Rhynhart, R. O. Snyder, and M. S. Conte. 2000. Gene delivery to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors. J. Vasc. Surg. 31:1149-1159.
12. Greber, U. F., M. Y. Nakano, and M. Suomalainen. 1998. Adenovirus entry into cells: A quantitative fluorescence approach. Methods Mol. Med. 21:217-230.
13. Grimm, D., A. Kern, K. Rittner, and J. A. Kleinschmidt. 1998. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9:2745-2760.
14. Gruenberg, J. 2001. The endocytic pathway: A mosaic of domains. Nat. Rev. Mol. Cell Biol. 2:721-730.
15. Halbert, C. L., E. A. Rutledge, J. M. Allen, D. W. Russell, and A. D. Miller. 2000. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74:1524-1532.
16. Hansen, J., K. Qing, and A. Srivastava. 2001. Adeno-associated virus type 2-mediated gene transfer: Altered endocytic processing enhances transduction efficiency in murine fibroblasts. J. Virol. 75:4080-4090.
17. Hansen, J., K. Qing, and A. Srivastava. 2001. Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 4:289-296.
18. Iozzo, R. V., and J. D. San Antonio. 2001. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J. Clin. Investig. 108:349-355.
19. Korhonen, J., I. Lahtinen, M. Halmekyto, L. Alhonen, J. Janne, D. Dumont, and K. Alitalo. 1995. Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood 86:1828-1835.
20. Monahan, P, E., and R. J. Samulski. 2000. Adeno-associated virus vectors for gene therapy: More pros than cons? Mol. Med. Today 6:433-440.
21. Nangia-Makker, P., S. Baccarini, and A. Raz. 2000. Carbohydrate-recognition and angiogenesis. Cancer Metastasis Rev. 19:51-57.
22. Nicklin, S. A., H. Buening, K. L. Dishart, M. de Alwis, A. Girod, U. Hacker, A. J. Thrasher, R. R. Ali, M. Hallek, and A. H. Baker. 2001. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4:174-181.
23. Paterna, J. C., T. Moccetti, A. Mura, J. Feldon, and H. Bueler. 2000. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther. 7:1304-1311.
24. Qing, K., C. Mah, J. Hansen, S. Zhou, V. Dwarki, and A. Srivastava. 1999. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77.
25. Richter, M., A. Iwata, J. Nyhuis, Y. Nitta, A. D. Miller, C. L. Halbert, and M. D. Allen. 2000. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol. Genomics 2:117-127.
26. Rivett, A. J. 1998. Intracellular distribution of proteasomes. Curr. Opin. Immunol. 10:110-114.
27. Rome, J. J., V. Shayani, M. Y. Flugelman, K. D. Newman, A. Farb, R. Virmani, and D. A. Dichek. 1994. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler. Thromb. 14:148-161.
28. Seisenberger, G., M. U. Ried, T. Endress, H. Buning, M. Hallek, and C. Brauchle. 2001. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 294:1929-1932.
29. Smith-Arica, J. R., and J. S. Bartlett. 2001. Gene therapy: Recombinant adeno-associated virus vectors. Curr. Cardiol. Rep. 3:43-49.
30. Stupack, D. G., and D. A. Cheresh. 2002. ECM remodeling regulates angiogenesis: Endothelial integrins look for new ligands. Sci. STKE 119:E7.
31. Summerford, C., J. S. Bartlett, and R. J. Samulski. 1999. αVβ5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5:78-82.
32. Summerford, C., and R. J. Samulski. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
33. Teramoto, S., T. Ishii, T. Matsuse, and Y. Fukuchi. 2000. Recombinant adeno-associated virus vectors efficiently transduce foreign genes into bovine aortic endothelial cells: Comparison with adenovirus vectors. Jpn. J. Pharmacol. 84:206-212.
34. Tsou, R., and F. F. Isik. 2001. Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol. Cell Biochem. 224:81-89.
35. Turunen, M. P., M. O. Hiltunen, and S. Yla-Herttuala. 1999. Gene therapy for angiogenesis, restenosis and related diseases. Exp. Gerontol. 34:567-574.
36. Van Meir, E., Y. Sawamura, A. C. Diserens, M. F. Hamou, and N. de Tribolet. 1990. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 50:6683-6688.
37. Walters, R. W., S. M. Yi, S. Keshavjee, K. E. Brown, M. J. Welsh, J. A. Chiorini, and J. Zabner. 2001. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276:20610-20616.
38. Yan, Z., R. Zak, G. W. Luxton, T. C. Ritchie, U. Bantel-Schaal, and J. F. Engelhardt. 2002. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76:2043-2053.
39. Yang, Z., F. Ruschitzka, T. J. Rabelink, G. Noll, F. Julmy, H. Joch, V. Gafner, I. Aleksic, U. Althaus, and T. F. Luscher. 1997. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation 95:1870-1876.
40. Yla-Herttuala, S., J. Luoma, H. Viita, T. Hiltunen, T. Sisto, and T. Nikkari. 1995. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J. Clin. Investig. 95:2692-2698.
41. Zolotukhin, S., B. J. Byrne, E. Mason, I. Zolotukhin, M. Potter, K. Chesnut, C. Summerford, R. J. Samulski, and N. Muzyczka. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:973-985.